Terug

Koninklijke DSM N.V.

Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.

  • Publicatie datum 14 feb 2007 - 08:01
  • Statutaire naam Koninklijke DSM N.V.
  • Titel DSM achieves record sales and operating profit in 2006, ahead of Vision 2010 objectives
  • Bericht • Operating profit for 2006 EUR 835 million, 6% higher than in 2005. • Net profit EUR 547 million, up 4% from 2005. • Solid volume growth (5%), especially in Performance Materials (9%). • Proposed dividend EUR 1.00 per ordinary share. • Outlook: Operating profit in 2007 expected to be lower than in 2006, but on track with Vision 2010. DSM and Crucell announce breakthrough in the production of biopharmaceuticals with PER.C6® technology platform. Royal DSM N.V. and Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX), today announce fermentation yields of more than 10 grams per liter for monoclonal antibodies, a major breakthrough in the development of their PER.C6 technology platform.

Gerelateerde downloads

200702140000000003_03-E-07-DSM and Crucell-PERC6 breakthrough.pdf
200702140000000003_04-E-07-DSM FY Results 2006.pdf

Datum laatste update: 20 november 2019

Informatie delen

Delen via: deel